Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE:BMY) will announce its third-quarter 2022 financial results on October 26, 2022, during a conference call at 8:00 a.m. ET. The call will include a review of the financial results and a Q&A session with investors and analysts. A live webcast is available for the public at investor.bms.com. The call can also be accessed via phone by dialing 877-502-9276 in the U.S. Participants can replay the call starting 11:30 a.m. ET on the same day until November 9, 2022.
Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. ET in New York City. Executive Vice Presidents Chris Boerner, Ph.D., and Samit Hirawat, M.D., will address questions regarding the company's operations. A live webcast will be accessible at investor.bms.com, with an archived version available later that day.
Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.
Bristol Myers Squibb (NYSE: BMY) presented significant research at the ESMO Congress 2022, underscoring the impact of Opdivo (nivolumab) in treating various cancers. Key findings include positive long-term survival data from Opdivo-based therapies and supportive evidence for its combination with other agents in advanced melanoma, non-small cell lung cancer, and urothelial carcinoma. Over 90 studies will be showcased, emphasizing the ongoing commitment to cancer treatment and personalized medicine.
Bristol Myers Squibb (NYSE: BMY) will participate in Citi’s 17th Annual BioPharma Conference on September 8, 2022, in Boston, Massachusetts. The session is scheduled for 8:50 a.m. ET, where company executives will address questions regarding the firm. Investors and the public can listen to a live webcast of the event on BMS.com, with an archived version available later the same day. Bristol Myers Squibb is dedicated to developing innovative medicines to combat serious diseases.
Bristol Myers Squibb (NYSE:BMY) reported promising results from the Phase 2 AXIOMATIC-SSP study on milvexian, an oral factor XIa inhibitor, showing a ~30% relative risk reduction in symptomatic ischemic strokes compared to placebo. Notably, there were no instances of fatal bleeding or increased symptomatic intracranial hemorrhage among patients treated with milvexian. These findings suggest potential for milvexian in improving outcomes for stroke patients, warranting further Phase 3 studies.
Bristol Myers Squibb (NYSE:BMY) has completed its acquisition of Turning Point Therapeutics in an all-cash deal valued at $76 per share. This acquisition enhances BMY's oncology portfolio, particularly with Turning Point’s lead asset, repotrectinib, aimed at ROS1-positive non-small cell lung cancer patients. The drug has shown promising results in clinical trials and is expected to receive FDA approval in the second half of 2023. Approximately 84% of Turning Point’s shares were tendered in the offer, finalizing its status as a wholly owned subsidiary of BMY.
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) announced the expiration of the waiting period under the HSR Act, receiving merger control clearance from the Federal Cartel Office of Germany. The acquisition offer to buy all outstanding shares of Turning Point for $76.00 per share, totaling approximately $4.1 billion, is set to close on August 17, 2022. Approximately 41.9 million shares, or 84% of Turning Point's outstanding shares, were validly tendered as of the Offer's expiration on August 15, 2022.
Bristol Myers Squibb (NYSE: BMY) and 2seventy bio (NASDAQ: TSVT) announced positive topline results from the Phase 3 KarMMa-3 study, evaluating Abecma (idecabtagene vicleucel) in relapsed and refractory multiple myeloma. The trial met its primary endpoint, showing statistically significant improvement in progression-free survival versus standard treatments. Key secondary endpoints, including overall response rate, also showed improvement. No new safety signals were reported, confirming Abecma's well-established safety profile.
Bristol Myers Squibb (NYSE: BMY) announced a virtual Investor Event on August 28, 2022, at 7:00 p.m. CET / 1:00 p.m. ET. The event will discuss data from the AXIOMATIC-SSP Phase 2 trial of milvexian for secondary stroke prevention presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain. Executives will offer insights on the data and answer investor questions. Interested parties can access the live webcast on the company's investor relations website, with archived content available later the same day.
Bristol Myers Squibb (NYSE: BMY) announced that Part A of the Phase 3 CheckMate -914 trial did not meet its primary endpoint of disease-free survival for the combination therapy of Opdivo and Yervoy in patients with localized renal cell carcinoma after kidney surgery. Despite previous successes in treating other stages of RCC, this trial's outcome is disappointing. The company remains committed to research in this area and will evaluate the data for further insights.